Last10K.com

Cardiff Oncology, Inc. (CRDF) SEC Filing 8-K Material Event for the period ending Monday, June 15, 2020

Cardiff Oncology, Inc.

HISTORY TOOLS
CIK: 1113809 Ticker: CRDF

View differences made from one to another to evaluate Cardiff Oncology, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Cardiff Oncology, Inc..

Continue

Assess how Cardiff Oncology, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Cardiff Oncology, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Cardiff Oncology, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: CRDF
CIK: 1213037
Form Type: 8-K Corporate News
Accession Number: 0001628280-20-009417
Submitted to the SEC: Mon Jun 15 2020 11:50:22 AM EST
Accepted by the SEC: Mon Jun 15 2020
Period: Monday, June 15, 2020
Industry: Biological Products No Disgnostic Substances
Events:
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/crdf/0001628280-20-009417.htm